In December 2005, Eli Lilly and Business agreed to plead responsible and spend $36 million in reference to the unlawful advertising of your drug.[264] Revenue Associates ended up qualified to promote Evista for breast cancer and cardiovascular disease, to prompt or bait questions by doctors, and